PR View by Susan Isenberg

In today's trust-bereft marketplace, it's engagement that people crave, and engagement that builds trust. These are among the findings of the Edelman Health Engagement Barometer—a 5,000 person, five-country study that looked at perspectives on how people want health companies, organizations, brands and services to engage with them. Trust and health engagement form a virtuous circle—with one fueling the other and together supporting a company's license to operate.

Additional findings point to the desire for complete transparency, with information specific to personal health being communicated by knowledgeable, authenticated sources. This new era of public engagement calls for organizations and brands to make deeper, more open connections, and to authentically interact with their publics without seeking to control these interactions. And no one source is the most trusted: Today's publics scour multiple sources for validation of health information. 

Findings from Edelman's 10th Trust Barometer support these conclusions: It shows that informed publics demand a much more democratic approach to running, shaping and driving business. Various publics expect business, governments and NGOs to collaborate on serious issues, including access to healthcare. Without effective engagement with all stakeholders, building trusting relationships with regulators and customers is impossible. So let's pay heed to this virtuous circle.

Susan Isenberg is managing director, health, US at Edelman
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.